Oncology Biomarker Conference London

Discovery to translation

Why discovery tools belong at an oncology biomarker conference London teams use

For vendors of spatial, single-cell, ctDNA, digital pathology and AI discovery tools, ImmunoMark Summit is the oncology biomarker conference London translational teams use to judge which technologies are ready to leave the discovery lab.

Early-pipeline tools have a specific sales problem. The scientist who loves your data is rarely the person who funds a translational study, and the person who funds it wants to know whether the readout will survive into a clinical assay. At ImmunoMark London (3–4 March 2027) both sit in the same Stream 2 sessions. The 2027 Key Highlights for Stream 2 include “Multi-omics, spatial biology and liquid biopsy platforms” and “AI and machine learning in biomarker discovery”, and the 2026 edition covered liquid biopsy and real-time monitoring, multi-omics and single-cell technologies, and AI-driven biomarker discovery platforms.

Spatial biology

Buyers want to know whether spatial context changes a go/no-go call. Relevant session: Digital Pathology & Spatial Transcriptomics in Oncology.

Single-cell and multi-omics

Translational teams ask how many samples, at what cost, before a signature is credible. Relevant session: Functional T cell Biomarkers for Precision Immuno-Oncology.

ctDNA and liquid biopsy

The question is longitudinal: can a blood readout track response in an IO trial? Liquid biopsy platforms sit in the 2027 Stream 2 highlights.

Digital pathology and AI

Buyers test whether an algorithm adds information beyond the pathologist. Relevant session: The Future of Biomarker-Driven Oncology.

Agenda themes

The discovery-stage sessions on the London 2027 agenda

These sessions from the published London 2027 agenda are where discovery and translational buyers will be in the room. Use them to plan which sessions your team covers and who you book meetings with.

Day 1 · Stream 2Leveraging Space Genomics to Discover Novel Biomarkers and Identify Emerging Therapeutic Strategies (Norris Igbineweka, Vertex Pharmaceuticals)
Day 1 · Stream 2The Future of Biomarker-Driven Oncology
Day 1 · Stream 2Digital Pathology & Spatial Transcriptomics in Oncology
Day 2 · Stream 2Keynote: Emerging Predictive & Prognostic Biomarkers in IO
Day 2 · Stream 2Functional T cell Biomarkers for Precision Immuno-Oncology (Marc Vendrell, The University of Edinburgh)
Day 2 · Stream 2Multiplex & Programmable Biomarker Platforms
Day 2 · Stream 1Translational Research: Bridging Academia & Industry

That mix is what makes this a cancer biomarker conference London discovery vendors can sell at: the talks move from new biology to the question of what a biomarker has to prove before it is used in a trial. The 2027 speaker panel also includes Qingli (Ramina) Guo, Senior Data Scientist at The Francis Crick Institute, and Arijit Patra, Senior Principal Scientist at UCB.

If you want the technical background your buyers are working from, our explainer on spatial proteomics vs spatial transcriptomics is a useful primer to share with your field team.

The UK cluster

A biomarker conference UK discovery teams can reach in a day

Sixty per cent of London delegates come from the UK and Ireland. For a discovery-tool vendor, that means one trip covers the London, Oxford and Cambridge research corridor and the rest of the UK’s translational base.

London

The 2027 speaker panel includes The Francis Crick Institute and LifeArc, and 2026 participants included UK biotechs such as ValiRx and Leucid Bio.

Oxford and Cambridge

Both are a short train journey from London, so translational teams there can join for a day without the cost of an overseas trip. The University of Oxford was on the 2026 speaker panel.

Beyond the triangle

Speakers in 2026 and 2027 came from the Universities of Southampton, Edinburgh, Manchester and Warwick, and 40% of delegates travel from continental Europe.

Academic and research roles make up 10–15% of delegates and scientists, PIs and technologists 20–30%. Most of the room is industry: 55–60% biotech and pharma. That balance suits a discovery-tool vendor, because the academic users who validate your method and the industry teams who buy at scale meet in one place. Treat it as a biomarker discovery conference London buyers use with budgets attached, rather than a purely academic biomarker symposium London researchers visit for the science alone.

Packages

Packages for discovery and translational tool vendors

Discovery tools are usually sold on data. The right package gives you enough stage time to show an oncology application and enough meetings to follow it up.

Best fit

Gold (Stream 2)

A 30-minute talk on the Day 2 morning, the block that also carries the IO biomarkers keynote, Real-World Evidence Integration into Biomarker Strategy and Functional T cell Biomarkers. That puts an application-data talk among the discovery content.

30-minute Day 2 pre-lunch talk plus Q&A
6 pre-scheduled 1:1 meetings
10 x 6 ft booth
Attendee list a week before
6 + 6 passes; half-page brochure ad

Silver (Stream 2)

A 15-minute Day 2 post-lunch slot, just before the Global CDx Approval Pathways panel and Multiplex & Programmable Biomarker Platforms. Good for a single, tight case study.

15-minute talk plus Q&A
10 x 6 ft booth
4 + 4 passes
No pre-scheduled meetings

Exclusive 1:1 Meetings

For early-stage companies with a strong method but no talk ready yet. Start with 3 or 5 meetings with the translational leads on your shortlist.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Wishlist and delegate list

Platinum and Headline add more meetings and a Day 1 stage. Compare everything on the London sponsorship opportunities page or run your numbers in the ROI calculator below.

Planning checklist

Getting ready for the biomarker conference UK 2027 calendar

A short checklist for discovery-tool teams preparing for 3–4 March 2027.

Before you commit

Pick one oncology application to lead with, not your whole platform
Decide whether you have customer or in-house oncology data strong enough for a talk
Choose Stream 2 unless your main use case is immune monitoring in IO trials
List the 20 accounts you most want to meet

In the run-up

Use the wishlist feature to flag translational and biomarker discovery leads
Pick your meetings from the full delegate list sent 10 days before
Prepare a one-page data summary per meeting
Plan who covers which Stream 2 session

For a platform-by-platform view across all editions, see liquid biopsy, spatial and multiplex platforms at ImmunoMark. If you sell across the whole Stream 2 audience rather than discovery alone, see the biomarker conference London overview. For reagents, models and preclinical services, the cancer conference London page covers the research end of the market.

Send us your technology and target accounts and we will suggest where your talk and meetings should sit.

Talk to the sponsorship team

Sponsorship ROI calculator

What could London 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every £1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package Or talk to our team about a custom package

Estimates only, based on the numbers you enter. Meetings and inclusions from the London 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Is ImmunoMark London relevant if our tool is used at the discovery stage?

Yes. Stream 2 covers discovery as well as validation and CDx, with London 2027 sessions such as Leveraging Space Genomics to Discover Novel Biomarkers, Digital Pathology & Spatial Transcriptomics in Oncology and Multiplex & Programmable Biomarker Platforms. Scientists, PIs and technologists make up 20–30% of delegates, alongside 45–50% senior leadership.

Does the London 2027 agenda cover ctDNA and liquid biopsy?

Multi-omics, spatial biology and liquid biopsy platforms are listed among the Stream 2 highlights for London 2027, and liquid biopsy and real-time monitoring was a Stream 2 theme in 2026. The published 2027 agenda does not yet list a session titled specifically on ctDNA, so ask the team for the latest programme if that is your main use case.

Where would a Gold sponsor's talk sit?

Gold includes a 30-minute talk on Day 2, pre-lunch, in the stream you choose. In Stream 2 the Day 2 morning also includes the keynote on Emerging Predictive & Prognostic Biomarkers in IO, Real-World Evidence Integration into Biomarker Strategy and Functional T cell Biomarkers for Precision Immuno-Oncology.

How much of the London audience is UK-based?

Delegate geography for London is 60% UK & Ireland and 40% rest of Europe. By sector, 55–60% are from biotech and pharma, 10–15% from academia, 5–10% clinicians and about 5% from government, regulatory and industry bodies.

We are a start-up. What is the smallest way to take part?

The Exhibitor package (10 x 6 ft booth, 2 + 2 passes, delegate list, wishlist and logo on the website and in the brochure) and the Exclusive 1:1 Meetings package with 3 pre-arranged 20-minute meetings are the entry points. Both include the delegate list with contact details.

Oncology Biomarker Conference London for Discovery Tool Vendors

Get the prospectus and package availability